Brief: SAB BIO Reports Strong Cash Position With Completed Financing Extending Operational Runway
07/08/2025 13:07
Aug 7 (Reuters) - SAB Biotherapeutics Inc SABS.O: SAB BIOTHERAPEUTICS INC: STRONG CASH POSITION WITH COMPLETED FINANCING EXTENDING OPERATIONAL RUNWAY UNTIL MIDDLE OF 2028 SAB BIOTHERAPEUTICS INC: SAFEGUARD STUDY TO INITIATE IN Q3 2025 Source text: ID:nGNX9M0yFp Further company coverage: SABS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies